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Inhaled tobramycin is one of the cornerstone therapies for
chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Monitoring of serum levels of aminoglycosides is essential when
using intravenous formulations to prevent potential toxicity. The
use of fingerprick blood sampling is now an established method
of monitoring tobramycin levels and is less invasive than
conventional phlebotomy [1]. Case reports have identified a
potential risk of falsely elevated tobramycin levels using this
sampling method if the patient is on concurrent nebulised
tobramycin due to skin contamination [2,3]. This has led to the
recommendation to avoid the use of fingerprick blood sampling
in patients utilising the dry powder inhaled form [4], but the
validity of this has not been reported in the literature. We report
for the first time a falsely elevated tobramycin level secondary
to skin contamination from the dry powder inhaled form of
tobramycin.
A 19 year old gentleman commenced tobramycin by dry
powder inhaler in addition to once daily intravenous tobramycin
in order to establish regular maintenance therapies prior to
discharge following a pulmonary exacerbation. A fingerprick
tobramycin level timed as trough for the intravenous dosing☆ Funding: None.
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a serum sample was repeated immediately after reporting,
yielding a result of 0.2 mg/L. This case clearly indicates the
potential for misleading tobramycin levels secondary to skin
contamination when using the new dry powder inhaled form of
tobramycin. Clinicians should be aware of this possibility when
interpreting fingerprick tobramycin levels in a patient on any of
the available inhaled formulations of tobramycin.
References
[1] Jones AM, Biesty J, McKenna D, Clough D, Webb AK, Morris J, Keevil B.
Monitoring of tobramycin levels in patients with cystic fibrosis by finger-
prick sampling. Eur Respir J 2012;39:1537–8.
[2] Struthers SL, Nicholson T, Jones G, Connett GJ. Falsely elevated serum
tobramycin levels in a patient receiving nebulised tobramycin. J Cyst Fibros
2002;1:146–7.
[3] Redmann S, Wainwright C, Stacey S, Champion A, Mitchell P, Cheney J,
Charles B. Misleading high tobramycin plasma concentrations can be
caused by skin contamination of fingerprick blood following inhalation
of nebulized tobramycin (TOBI): a short report. Ther Drug Monit
2005;27:205–7.
[4] Tobi Podhaler: EPAR—product information. http://www.ema.europa.eu/
ema/index.jsp?curl=pages/medicines/human/medicines/002155/human_
med_001401.jsp&mid=WC0b01ac058001d124 . [Accessed March 2014].ll rights reserved.
